CHCHD3

Across TCGA pan-cancer cohorts, CHCHD3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHCHD3 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CHCHD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHCHD3 expression acts as an unfavorable survival marker.

CESC, KIRC, and OV are the cancer types where CHCHD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.047	0.875	<.001	24	view →
KIRC	OS	Median	All	0.138	0.655	.019	12	view →
OV	OS	Median	II,III,IV	0.324	0.691	.049	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CHCHD3–CESC (OS)

Open the CESC breakdown →